S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
As Musk is learning, content moderation is a messy job
Intel is a Sleeping Giant Ready to Awaken
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
FDA change ushers in cheaper, easier-to-get hearing aids
Reformers take 6 of 14 UAW board seats, could win majority
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
As Musk is learning, content moderation is a messy job
Intel is a Sleeping Giant Ready to Awaken
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
FDA change ushers in cheaper, easier-to-get hearing aids
Reformers take 6 of 14 UAW board seats, could win majority
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
As Musk is learning, content moderation is a messy job
Intel is a Sleeping Giant Ready to Awaken
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
FDA change ushers in cheaper, easier-to-get hearing aids
Reformers take 6 of 14 UAW board seats, could win majority
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
As Musk is learning, content moderation is a messy job
Intel is a Sleeping Giant Ready to Awaken
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
FDA change ushers in cheaper, easier-to-get hearing aids
Reformers take 6 of 14 UAW board seats, could win majority
NASDAQ:FOLD

Amicus Therapeutics - FOLD Stock Forecast, Price & News

$12.70
+0.42 (+3.42%)
(As of 12/2/2022 09:00 PM ET)
Add
Compare
Today's Range
$12.12
$12.72
50-Day Range
$9.99
$12.70
52-Week Range
$5.91
$12.96
Volume
2.24 million shs
Average Volume
3.16 million shs
Market Capitalization
$3.57 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.67

Amicus Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
15.5% Upside
$14.67 Price Target
Short Interest
Bearish
6.72% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.17
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$698,952 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.78) to ($0.23) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.42 out of 5 stars

Medical Sector

972nd out of 1,033 stocks

Pharmaceutical Preparations Industry

474th out of 502 stocks

FOLD stock logo

About Amicus Therapeutics (NASDAQ:FOLD) Stock

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.

Receive FOLD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amicus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FOLD Stock News Headlines

SVB Securities Reaffirms Their Buy Rating on Amicus (FOLD)
Amicus Therapeutics Provides EU Regulatory Update for AT-GAA
Amicus says no oral explanations in EU for lead program
Recap: Amicus Therapeutics Q3 Earnings
Amicus Therapeutics Says FDA Defers Filing For AT-GAA
Amicus Therapeutics (NASDAQ: FOLD)
Amicus Therapeutics, Inc. (FOLD)
See More Headlines
Receive FOLD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amicus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FOLD Company Calendar

Last Earnings
11/08/2021
Today
12/05/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/23/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:FOLD
CUSIP
03152W10
Employees
496
Year Founded
2002

Price Target and Rating

Average Stock Price Forecast
$14.67
High Stock Price Forecast
$15.00
Low Stock Price Forecast
$14.00
Forecasted Upside/Downside
+15.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$-250,460,000.00
Pretax Margin
-78.03%

Debt

Sales & Book Value

Annual Sales
$305.51 million
Book Value
$0.47 per share

Miscellaneous

Free Float
274,202,000
Market Cap
$3.57 billion
Optionable
Optionable
Beta
0.90

Social Links


Key Executives

  • Mr. John F. CrowleyMr. John F. Crowley (Age 55)
    Exec. Chairman
    Comp: $2.06M
  • Mr. Bradley L. Campbell M.B.A.Mr. Bradley L. Campbell M.B.A. (Age 46)
    CEO, Pres & Director
    Comp: $947.8k
  • Ms. Daphne E. Quimi CPA (Age 56)
    M.B.A., Chief Financial Officer
    Comp: $785.38k
  • Ms. Ellen S. Rosenberg (Age 59)
    Chief Legal Officer & Corp. Sec.
    Comp: $771.52k
  • Mr. David M. Clark (Age 47)
    Chief People Officer
    Comp: $738.22k
  • Ms. Samantha Prout (Age 44)
    VP, Global Controller & Principal Accounting Officer
  • Dr. Jill Weimer Ph.D.
    Chief Science Officer
  • Andrew Faughnan
    Sr. Director of Investor Relations
  • Mr. Patrik S. Florencio
    Sr. VP, Global Chief Compliance & Risk Officer
  • Ms. Diana Moore
    Head of Global Corp. Communications













FOLD Stock - Frequently Asked Questions

Should I buy or sell Amicus Therapeutics stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amicus Therapeutics in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" FOLD shares.
View FOLD analyst ratings
or view top-rated stocks.

What is Amicus Therapeutics' stock price forecast for 2023?

4 Wall Street analysts have issued 12-month price targets for Amicus Therapeutics' shares. Their FOLD share price forecasts range from $14.00 to $15.00. On average, they anticipate the company's share price to reach $14.67 in the next twelve months. This suggests a possible upside of 15.5% from the stock's current price.
View analysts price targets for FOLD
or view top-rated stocks among Wall Street analysts.

How have FOLD shares performed in 2022?

Amicus Therapeutics' stock was trading at $11.55 at the beginning of 2022. Since then, FOLD stock has increased by 10.0% and is now trading at $12.70.
View the best growth stocks for 2022 here
.

When is Amicus Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our FOLD earnings forecast
.

How were Amicus Therapeutics' earnings last quarter?

Amicus Therapeutics, Inc. (NASDAQ:FOLD) posted its quarterly earnings data on Monday, November, 8th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.18) by $0.01. The biopharmaceutical company had revenue of $79.55 million for the quarter, compared to analysts' expectations of $81.42 million. Amicus Therapeutics had a negative trailing twelve-month return on equity of 123.94% and a negative net margin of 81.65%. During the same period in the prior year, the company posted ($0.22) EPS.

What is John F. Crowley's approval rating as Amicus Therapeutics' CEO?

21 employees have rated Amicus Therapeutics Chief Executive Officer John F. Crowley on Glassdoor.com. John F. Crowley has an approval rating of 48% among the company's employees. This puts John F. Crowley in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Amicus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amicus Therapeutics investors own include NVIDIA (NVDA), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Sangamo Therapeutics (SGMO), Sarepta Therapeutics (SRPT), AbbVie (ABBV), Exelixis (EXEL), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO) and Novavax (NVAX).

What is Amicus Therapeutics' stock symbol?

Amicus Therapeutics trades on the NASDAQ under the ticker symbol "FOLD."

Who are Amicus Therapeutics' major shareholders?

Amicus Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Perceptive Advisors LLC (9.74%), Vanguard Group Inc. (9.21%), BlackRock Inc. (7.08%), State Street Corp (4.28%), Macquarie Group Ltd. (2.45%) and Fiera Capital Corp (1.43%). Insiders that own company stock include Bradley L Campbell, Bradley L Campbell, Burke W Whitman, Burke W Whitman, Daphne Quimi, Ellen Rosenberg, Hung Do, Jay Barth, John F Crowley, John F Crowley, Lynn Dorsey Bleil, Margaret G Mcglynn, Michael Raab and Samantha Prout.
View institutional ownership trends
.

How do I buy shares of Amicus Therapeutics?

Shares of FOLD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amicus Therapeutics' stock price today?

One share of FOLD stock can currently be purchased for approximately $12.70.

How much money does Amicus Therapeutics make?

Amicus Therapeutics (NASDAQ:FOLD) has a market capitalization of $3.57 billion and generates $305.51 million in revenue each year. The biopharmaceutical company earns $-250,460,000.00 in net income (profit) each year or ($0.92) on an earnings per share basis.

How many employees does Amicus Therapeutics have?

The company employs 496 workers across the globe.

How can I contact Amicus Therapeutics?

Amicus Therapeutics' mailing address is 1 Cedar Brook Drive, Cranbury NJ, 08512. The official website for the company is www.amicusrx.com. The biopharmaceutical company can be reached via phone at (215) 921-7600, via email at afaughnan@amicusrx.com, or via fax at 609-662-2001.

This page (NASDAQ:FOLD) was last updated on 12/5/2022 by MarketBeat.com Staff